

**REMARKS**

The claims currently pending are drawn to compositions and methods to use them. The proposed new claims are directed to methods to prepare these compositions. Applicants inadvertently omitted these claims from the application as originally filed.

The new claims are proposed as they are believed distinct from a document of record, CH 681,780. This document was submitted as part of an Information Disclosure Statement filed along with the application.

Applicants believe that the proposed claims 42-46, directed to a method to prepare a composition do not lack unity. It is further noted that an election of species was required as to drugs, drug resistance modulators and delivery vehicles. The present claims are already limited to liposomes as delivery vehicles and the drugs are already limited to antineoplastic agents. If the Examiner wishes an arbitrarily chosen starting point for drugs that represent a single drug, applicants arbitrarily select carboplatin as the antineoplastic drug. This drug is mentioned among many in paragraph 47. A starting point for the drug resistance modulator is miltefosine mentioned at the end of paragraph 31.

Applicants understand that these are merely starting points for examination and that should this specific combination be found patentable, additional embodiments and generic claims will eventually be examined.

Support for the claims as proposed is found in paragraph 18, and in the description of the method in paragraphs 49-59 and in Example 1.

Thus, these claims do not represent new matter or present an undue search burden.

Entry of the amendment and examination on the merits is respectfully requested.

